Presence and Type of Cribriform Pattern (CP) 4 in Prostate Biopsies (Bx) with Gleason Score (GS) 7 Prostate Cancer (PCa) is Significantly Associated with High-Risk Clinical Features (HRF)

被引：0
|
作者：
Gupta, Chhavi [1 ]
Iwata, Atsuko [2 ]
Amin, Mahul [3 ]
Sali, Akash [4 ]
Palmer, Suzanne [4 ]
Aliasger, Shakir [2 ]
Abreu, Andre [4 ]
Aron, Manju [4 ]
机构：
[1] Tata Mem Hosp, Mumbai, Maharashtra, India
[2] USC, Keck Med Ctr, Los Angeles, CA USA
[3] Methodist Univ Hosp, Memphis, TN USA
[4] Univ Southern Calif, Keck Sch Med, Los Angeles, CA 90007 USA
来源：
LABORATORY INVESTIGATION | 2020年 / 100卷 / SUPPL 1期
关键词：
D O I：
暂无
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
916
引用
收藏
页码：890 / 890
页数：1
相关论文
共 31 条
  • [21] Risk of Gleason Score 3+4=7 prostate cancer upgrading at radical prostatectomy is significantly reduced by targeted versus standard biopsy
    De Luca, Stefano
    Fiori, Cristian
    Bollito, Enrico
    Garrou, Diletta
    Aimar, Roberta
    Cattaneo, Giovanni
    De Cillis, Sabrina
    Manfredi, Matteo
    Tota, Daniele
    Federica, Massa
    Passera, Roberto
    Porpiglia, Francesco
    MINERVA UROLOGICA E NEFROLOGICA, 2020, 72 (03) : 360 - 368
  • [22] Re: Presence of Invasive Cribriform or Intraductal Growth at Biopsy Outperforms Percentage Grade 4 in Predicting Outcome of Gleason Score 3+4=7 Prostate Cancer Editorial Comment
    Taneja, Samir S.
    JOURNAL OF UROLOGY, 2017, 198 (04): : 745 - 745
  • [23] Prostate Cancer of Biopsy Gleason Score 3+4=7 with Less than 5% of Gleason Pattern 4 Component Is Associated with Significantly Lower Incidence of Adverse Pathology in Japanese Cohort: Suggestion for Active Surveillance Criteria
    Sato, Shun
    Kimura, Takahiro
    Yorozu, Takashi
    Ikegami, Masahiro
    Takahashi, Hiroyuki
    LABORATORY INVESTIGATION, 2018, 98 : 382 - 383
  • [24] Prostate Cancer of Biopsy Gleason Score 3+4=7 with Less than 5% of Gleason Pattern 4 Component Is Associated with Significantly Lower Incidence of Adverse Pathology in Japanese Cohort: Suggestion for Active Surveillance Criteria
    Sato, Shun
    Kimura, Takahiro
    Yorozu, Takashi
    Ikegami, Masahiro
    Takahashi, Hiroyuki
    MODERN PATHOLOGY, 2018, 31 : 382 - 383
  • [25] A 17-gene genomic prostate score (GPS) as a predictor of biochemical (BCR) and clinical recurrence (CR) in men with surgically treated intermediate- and high-risk prostate cancer (PCa).
    Klein, Eric A.
    Brand, Timothy
    Rosner, Inger L.
    Zhang, Nan
    Crager, Michael
    Maddala, Tara
    Febbo, Phillip G.
    Thomas, Shibu
    Gormley, Michael
    Ricci, Deborah S.
    Falzarano, Sara Moscovita
    Magi-Galluzzi, Cristina
    Cullen, Jennifer
    Sesterhenn, Isabel
    Lawrence, H. Jeffrey
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [26] A 17-gene genomic prostate score (GPS) as a predictor of biochemical (BCR) and clinical recurrence (CR) in men with surgically treated intermediate- and high-risk prostate cancer (PCa).
    Klein, Eric A.
    Zhang, Nan
    Crager, Michael
    Maddala, Tara
    Febbo, Phillip G.
    Thomas, Shibu
    Gormley, Michael
    Ricci, Deborah Sokol
    Falzarano, Sara Moscovita
    Magi-Galluzzi, Cristina
    Lawrence, H. Jeffrey
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (02)
  • [27] Gleason score, surgical and distant metastasis are associated with cancer-specific survival and overall survival in middle aged high-risk prostate cancer: A population-based study
    Cao, Guangbiao
    Li, Yan
    Wang, Jinkui
    Wu, Xin
    Zhang, Zhaoxia
    Zhanghuang, Chenghao
    Han, Keqiang
    FRONTIERS IN PUBLIC HEALTH, 2022, 10
  • [28] OUTCOME OF MULTIMODALITY TREATMENT OF HIGH-RISK LOCALIZED PROSTATE CANCER (CT3-4 OR PSA ≥20 NG/ML OR BIOPSY GLEASON SCORE ≥8) WITH RADICAL PROSTATECTOMY AS INITIAL STEP: A MULTI-INSTITUTIONAL OUTCOME STUDY OF 1413 PATIENTS
    Joniau, S. G.
    Spahn, M.
    Gontero, P.
    Tombal, B.
    Bangma, C.
    Walz, J.
    Hsu, C. Y.
    Van Der Eeckt, K.
    Marchioro, G.
    Bader, P.
    Frohneberg, D.
    Graefen, M.
    Huland, H.
    Schroder, F.
    Tizzani, A.
    Van Cangh, P.
    Van Poppel, H.
    EUROPEAN UROLOGY SUPPLEMENTS, 2009, 8 (04) : 252 - 252
  • [29] Outcome of multimodality treatment of high-risk localized prostate cancer (cT3-4 OR PSA ≥20 ng/ml OR biopsy Gleason score ≥8) with radical prostatectomy as initial step: a multi-institutional outcome study of 1413 patients
    Spahn, M.
    Gontero, P.
    Tombal, B.
    Bangma, C.
    Walz, J.
    Hsu, C. Y.
    van der Eeckt, K.
    Marchioro, G.
    Bader, P.
    Frohneberg, D.
    Graefen, M.
    Huland, H.
    Schroder, F.
    Tizzani, A.
    van Cangh, P.
    van Poppel, H.
    Joniau, S. G.
    ONKOLOGIE, 2010, 33 : 89 - 90
  • [30] OUTCOME OF MULTIMODALITY TREATMENT OF HIGH-RISK LOCALIZED PROSTATE CANCER (CT3-4 OR PSA ≥20 NG/ML OR BIOPSY GLEASON SCORE ≥8) WITH RADICAL PROSTATECTOMY AS INITIAL STEP: A MULTI-INSTITUTIONAL OUTCOME STUDY OF 1413 PATIENTS
    Joniau, Steven
    Spahn, Martin
    Gontero, Paolo
    Tombal, Bertrand
    Bangma, Chris H.
    Waz, Jochen
    Hsu, Chao-Yu
    Vander Eeckt, Kathy
    Marchioro, Giansilvio
    Bader, Pia
    Isbarn, Hendrik
    Frohneberg, Detlef
    Graefen, Markus
    Schroeder, Fritz H.
    Tizzani, Alessandro
    Van Cangh, Paul
    Van Poppel, Hein
    JOURNAL OF UROLOGY, 2009, 181 (04): : 574 - 575
1234